-+ 0.00%
-+ 0.00%
-+ 0.00%

Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026

PUBT·06/01/2026 12:06:19
Listen to the news
Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026
  • Aprea Therapeutics presented updated Phase 1 results for WEE1 inhibitor APR-1051 at ASCO 2026 on May 30.
  • Early data showed signs of tumor shrinkage in some endometrial cancer patients, with disease control in additional heavily pretreated solid tumors.
  • Side effects were described as manageable, supporting continued dose escalation and a path toward selecting a later-stage dose.
  • The trial is expanding enrollment into uterine serous carcinoma, with a separate expansion in platinum-resistant ovarian cancer.
  • Dose escalation and backfill expansion are expected to complete in Q2 2027, setting up potential Phase 2 planning.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010800PRIMZONEFULLFEED9729325) on June 01, 2026, and is solely responsible for the information contained therein.